Celgene Stock Hits New 52-Week High (CELG)

NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Thursday as it is currently trading at $135.30, above its previous 52-week high of $131.82 with 1.3 million shares traded as of 9:36 a.m. ET. Average volume has been 3.1 million shares over the past 30 days.

Celgene has a market cap of $51.99 billion and is part of the health care sector and drugs industry. Shares are up 59.4% year to date as of the close of trading on Wednesday.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Celgene Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..